European weight-loss drug developers have staged something of a comeback this week, as investors rotate into healthcare from AI-exposed momentum stocks.
View SourceEuropean weight-loss drug developers have staged something of a comeback this week, as investors rotate into healthcare from AI-exposed momentum stocks.
View Source